Innovent Bio (01801) announced that da Bertrand (fluotrateresetin tablets) has been approved by the China National Medical Products Administration (NMPA) Drug Evaluation Center for listing, and is used for advanced non-small cell lung cancer (NSCLC) adult patients with G12C mutation of rodent tumor virus cancer gene who have received at least one systemic treatment. Da Bertrand (fluotrateresetin tablets) is the first approved KRAS G12C inhibitor in China, which will benefit more lung cancer patients with KRAS G12C mutation in China.
Intelligent Finance Channel APP News, Innovent Bio (01801) announced that da Bertrand (fluotrateresetin tablets) has been approved by the China National Medical Products Administration (NMPA) Drug Evaluation Center for listing, and is used for advanced non-small cell lung cancer (NSCLC) adult patients with G12C mutation of rodent tumor virus cancer gene who have received at least one systemic treatment. Da Bertrand (fluotrateresetin tablets) is the first approved KRAS G12C inhibitor in China, which will benefit more lung cancer patients with KRAS G12C mutation in China.